ADR Biomedical Holdings Inc. (TYO:3750)
771.00
-6.00 (-0.77%)
Nov 18, 2026, 9:57 AM JST
ADR Biomedical Holdings Revenue
ADR Biomedical Holdings had revenue of 9.00M JPY in the quarter ending September 30, 2026, a decrease of -25.00%. This brings the company's total for the last twelve months to 98.00M, up 100.00% year-over-year. In the fiscal year ending March 31, 2026, ADR Biomedical Holdings had annual revenue of 50.00M, down -59.02%. That makes ADR Biomedical Holdings the 44,322nd largest company in the world by revenue and 3,865th in Japan.
Revenue (ttm)
98.00M
Revenue Growth
+100.00%
P/S Ratio
70.79
Revenue / Employee
7.54M
Employees
13
Market Cap
6.88B
Revenue by Segment
- Medical Business 95.64M 78.3%
- Real Asset Business 26.57M 21.7%
Fiscal year ended Mar 31, 2025 See the full ADR Biomedical Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 50.00M | -72.00M | -59.02% |
| Mar 31, 2025 | 122.00M | -1.44B | -92.18% |
| Mar 31, 2024 | 1.56B | -584.00M | -27.24% |
| Mar 31, 2023 | 2.14B | 809.00M | 60.60% |
| Mar 31, 2022 | 1.34B | -53.00M | -3.82% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| StemCell Institute | 2.81B |
| Carna Biosciences | 756.57M |
| OncoTherapy Science | 712.00M |
| Chiome Bioscience | 615.15M |
| Nano Holdings | 210.00M |
| CellSeed | 161.00M |
| Kubota Pharmaceutical Holdings | 12.77M |